Skip to main content
. 2020 Dec 21;10(2):615–625. doi: 10.1002/cam4.3638

FIGURE 3.

FIGURE 3

Progression‐free survival (PFS) and overall survival (OS) with respect to prior bevacizumab (BEV) exposure in mCRC patients who were treated with second‐line chemotherapy. This figure shows PFS (A) and OS (B) in patients with prior BEV exposure compared to those without prior BEV exposure